If it can go parabolic toward $2 in the short term, it would be good opportunity to raise cash to fund the commercialization project. That is still a risk and the higher the PPS, the easier it would be to accommodate and control that risk.
On the technical front, it has lots more room left to run. The daily RSI of 61 is still relatively low for a stock that has been beaten down so much. It should go for higher levels and take out the 200ma of $1.27. Just taking a breather, I think.
$1.27 is the next target because it is the 200 day moving average. 50 day ma was $1.08. If it goes over $1.27, it should sustain parabolic move toward possibly $1.40, I think.
You're ranting!! This remains a disastrous investment until I break even.
Why compare an apparelled to a medical device? The examples that you guys draw up are quite shocking.
Focus on vBloc for what it is rather than comparing rats to dogs.
"As a prior CFO I understand financing. What is your credentials?"
LOL.. You're a low-life, Bio! Get your condescending mentality out of here. With all your wonderful credentials, you are still the master at picking failed stocks and getting all irrational through Google alerts. Clown!
I'm not stuck at $1.44 for sentimental reasons. I made a choice not to average down until I see improved fundamentals. I'm not into chasing PPS and averaging down on hope. When the fundamentals on cashflow improve, I will consider my options at that point.
I don't think how people pay for the device is where the sees a problem. Market doesn't know with numbers what the demand picture really is. That is not known to any of us at this point. The actual demand needs to be quantified for the market to start thinking about the intrinsic value of the company.
Bio, let me start by pointing out that you are an idiot to even suggest that I am short.
FYI, dilution is the game in biotech unless you get a strategic partner. Either way, if the details are not disclosed, then you would be a clown to think dilution is off the table.
Dude, don't ever bring Apple in ETRM conversation. That logic is too flawed. Apple has enough money to manufacture 10,000 Model S without running into cashflow problems.
But how do you manufacture enough products when you don't have money to start the manufacturing process?
Cashflow is actually the most critical part of running any commercial project. Without the cashflow, business is as good as dead because you simply can't expand the operations on limited cash. Even if they have all the demand in the world, cashflow would cause a bottleneck that could lead to systemic failure.
We still need to know precisely what the actual demand is.
Two things we need to know:
1. Cash situation.
2. Demand status - quantifiable demand and not just projection based on opened station.
So far we know how many clinic are ready to start performing the procedures, and that is great. But smart money will start to ask questions around sustainable operations. If they don't have partnerships, then hopefully that PPS goes up fast enough to at least have an option to raise cash without killing shareholders.
Without sharing plans on how they would facilitate commercialization of vBloc, I'm not that optimistic as the risk still remains. That is really the big news. What was shared yesterday was already known. The stock rallied 16% but in reality, the PPS is still shhh given it was only 0.94 last week.
It remains to be seen if there is a follow through from tomorrow. Still stuck at $1.44.
Without lifestyle change commitment, nothing ever changes. VBLOC trials also made that clear as well. You can't have sustained weight loss without walking that thin line. Which means is not no magical treatment for "sustained" weight-loss.
Bid is currently 0.93 and Ask is 1.20. Not bad!
But we need high volume to break out of sub $1 and confirm change in trend. Still need them to elaborate on cash position as well.
At what cost, Bio? If you are dedicated to healthy lifestyle, you don't need a neurodevice. I am not convinced that market targeted by weight watchers as in that article would be willing to shell out 15k for something they can achieve without it. At 15k and with the moderate efficacy, VBLOC is an expensive option unless hugely subsidized. I personally think that the value of the device is far better when addressed from perspective beyond obesity. That's because obesity is mostly tied to socioeconomic factors but other diseases are more diverse across the class spectrum which enhances the target audience. That would be the better story to tell.